FSM Wealth Advisors LLC Has $478,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

FSM Wealth Advisors LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 3.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,138 shares of the company’s stock after acquiring an additional 188 shares during the period. FSM Wealth Advisors LLC’s holdings in AstraZeneca were worth $478,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its holdings in shares of AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after buying an additional 9,002,450 shares in the last quarter. Capital World Investors increased its stake in AstraZeneca by 0.3% during the 1st quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after acquiring an additional 29,497 shares during the period. Envestnet Asset Management Inc. raised its position in shares of AstraZeneca by 16.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after buying an additional 488,644 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of AstraZeneca by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after buying an additional 186,010 shares in the last quarter. Finally, Fayez Sarofim & Co lifted its stake in AstraZeneca by 4.7% in the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after purchasing an additional 134,784 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AZN has been the topic of a number of recent research reports. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Price Performance

AZN stock opened at $71.43 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company’s 50-day moving average is $78.87 and its 200-day moving average is $78.77. The stock has a market capitalization of $221.48 billion, a PE ratio of 34.51, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.